Video
Novel Targets, Classes of Agents Could Refine Checkpoint Inhibition in NSCLC
Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions
The OncFive: Top Oncology Articles for the Week of 8/25
Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer
Revisit Every OncLive On Air Episode From August 2024
Merck to Discontinue KEYNOTE-867 and KEYNOTE-630 Trials of Pembrolizumab in NSCLC, CSCC
Subcutaneous Rituximab Remains Underutilized in Non-Hodgkin Lymphoma
Dr Seymour on the Role of Mutational Profiling in CLL
Liso-Cel Elicits Consistent Responses in R/R CLL/SLL, Irrespective of High-Risk Features
Valemetostat Demonstrates Clinically Meaningful Efficacy in R/R PTCL
%20(2)%201-Recovered-Recovered.jpg?fit=crop&auto=format)
